Impairment of the opioidergic control of luteinizing hormone secretion in Turner's syndrome: Lack of effect of gonadal steroid therapy

F. Petraglia, D. Larizza, M. Maghnie, F. Facchinetti, A. Volpe, S. Bernasconi, A. R. Genazzani, F. Severi

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

We studied the activity of endogenous opioid peptides in regulating LH secretion in patients with Turner's syndrome. To do so, we determined the LH secretory response to opiate receptor blockade by naloxone (0.08 mg/kg BW, iv) in 17 patients (age range, 9-23 yr). Eight patients were untreated (3 of whom had had spontaneous menarche), and 9 patients were taking ethinyl estradiol/medroxyprogesterone acetate treatment (5 of these patients were also studied before treatment). In addition, the plasma LH responses to GnRH (50 μg, iv) and placebo were determined in the patients as well as in 13 age-matched normal girls (6 prepubertal and 7 pubertal). Naloxone did not increase plasma LH levels in the amenorrheic untreated and treated patients with Turner's syndrome. However, in 3 patients who had had spontaneous menarche and in normal pubertal girls naloxone increased plasma LH levels. GnRH was effective to the same extent in the patients and normal subjects. These results indicate that in patients with Turner's syndrome the opioidergic inhibition of LH secretion is impaired and is not restored by gonadal steroid replacement therapy. Moreover, the normal plasma LH responses to naloxone in the spontaneously menstruating patients with Turner's syndrome indicate both the clinical variability of this syndrome and the participation of endogenous opioid peptides in the regulation of normal menstrual function.

Original languageEnglish
Pages (from-to)1024-1028
Number of pages5
JournalJournal of Clinical Endocrinology and Metabolism
Volume66
Issue number5
Publication statusPublished - 1988

Fingerprint

Turner Syndrome
Naloxone
Luteinizing Hormone
Steroids
Plasmas
Opioid Peptides
Gonadotropin-Releasing Hormone
Medroxyprogesterone Acetate
Ethinyl Estradiol
Opioid Receptors
Therapeutics
Menarche
Placebos

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Impairment of the opioidergic control of luteinizing hormone secretion in Turner's syndrome : Lack of effect of gonadal steroid therapy. / Petraglia, F.; Larizza, D.; Maghnie, M.; Facchinetti, F.; Volpe, A.; Bernasconi, S.; Genazzani, A. R.; Severi, F.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 66, No. 5, 1988, p. 1024-1028.

Research output: Contribution to journalArticle

@article{02df8560fa044940a40291e421554bb3,
title = "Impairment of the opioidergic control of luteinizing hormone secretion in Turner's syndrome: Lack of effect of gonadal steroid therapy",
abstract = "We studied the activity of endogenous opioid peptides in regulating LH secretion in patients with Turner's syndrome. To do so, we determined the LH secretory response to opiate receptor blockade by naloxone (0.08 mg/kg BW, iv) in 17 patients (age range, 9-23 yr). Eight patients were untreated (3 of whom had had spontaneous menarche), and 9 patients were taking ethinyl estradiol/medroxyprogesterone acetate treatment (5 of these patients were also studied before treatment). In addition, the plasma LH responses to GnRH (50 μg, iv) and placebo were determined in the patients as well as in 13 age-matched normal girls (6 prepubertal and 7 pubertal). Naloxone did not increase plasma LH levels in the amenorrheic untreated and treated patients with Turner's syndrome. However, in 3 patients who had had spontaneous menarche and in normal pubertal girls naloxone increased plasma LH levels. GnRH was effective to the same extent in the patients and normal subjects. These results indicate that in patients with Turner's syndrome the opioidergic inhibition of LH secretion is impaired and is not restored by gonadal steroid replacement therapy. Moreover, the normal plasma LH responses to naloxone in the spontaneously menstruating patients with Turner's syndrome indicate both the clinical variability of this syndrome and the participation of endogenous opioid peptides in the regulation of normal menstrual function.",
author = "F. Petraglia and D. Larizza and M. Maghnie and F. Facchinetti and A. Volpe and S. Bernasconi and Genazzani, {A. R.} and F. Severi",
year = "1988",
language = "English",
volume = "66",
pages = "1024--1028",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "5",

}

TY - JOUR

T1 - Impairment of the opioidergic control of luteinizing hormone secretion in Turner's syndrome

T2 - Lack of effect of gonadal steroid therapy

AU - Petraglia, F.

AU - Larizza, D.

AU - Maghnie, M.

AU - Facchinetti, F.

AU - Volpe, A.

AU - Bernasconi, S.

AU - Genazzani, A. R.

AU - Severi, F.

PY - 1988

Y1 - 1988

N2 - We studied the activity of endogenous opioid peptides in regulating LH secretion in patients with Turner's syndrome. To do so, we determined the LH secretory response to opiate receptor blockade by naloxone (0.08 mg/kg BW, iv) in 17 patients (age range, 9-23 yr). Eight patients were untreated (3 of whom had had spontaneous menarche), and 9 patients were taking ethinyl estradiol/medroxyprogesterone acetate treatment (5 of these patients were also studied before treatment). In addition, the plasma LH responses to GnRH (50 μg, iv) and placebo were determined in the patients as well as in 13 age-matched normal girls (6 prepubertal and 7 pubertal). Naloxone did not increase plasma LH levels in the amenorrheic untreated and treated patients with Turner's syndrome. However, in 3 patients who had had spontaneous menarche and in normal pubertal girls naloxone increased plasma LH levels. GnRH was effective to the same extent in the patients and normal subjects. These results indicate that in patients with Turner's syndrome the opioidergic inhibition of LH secretion is impaired and is not restored by gonadal steroid replacement therapy. Moreover, the normal plasma LH responses to naloxone in the spontaneously menstruating patients with Turner's syndrome indicate both the clinical variability of this syndrome and the participation of endogenous opioid peptides in the regulation of normal menstrual function.

AB - We studied the activity of endogenous opioid peptides in regulating LH secretion in patients with Turner's syndrome. To do so, we determined the LH secretory response to opiate receptor blockade by naloxone (0.08 mg/kg BW, iv) in 17 patients (age range, 9-23 yr). Eight patients were untreated (3 of whom had had spontaneous menarche), and 9 patients were taking ethinyl estradiol/medroxyprogesterone acetate treatment (5 of these patients were also studied before treatment). In addition, the plasma LH responses to GnRH (50 μg, iv) and placebo were determined in the patients as well as in 13 age-matched normal girls (6 prepubertal and 7 pubertal). Naloxone did not increase plasma LH levels in the amenorrheic untreated and treated patients with Turner's syndrome. However, in 3 patients who had had spontaneous menarche and in normal pubertal girls naloxone increased plasma LH levels. GnRH was effective to the same extent in the patients and normal subjects. These results indicate that in patients with Turner's syndrome the opioidergic inhibition of LH secretion is impaired and is not restored by gonadal steroid replacement therapy. Moreover, the normal plasma LH responses to naloxone in the spontaneously menstruating patients with Turner's syndrome indicate both the clinical variability of this syndrome and the participation of endogenous opioid peptides in the regulation of normal menstrual function.

UR - http://www.scopus.com/inward/record.url?scp=0023917493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023917493&partnerID=8YFLogxK

M3 - Article

C2 - 3129445

AN - SCOPUS:0023917493

VL - 66

SP - 1024

EP - 1028

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 5

ER -